Skip to main navigation

This website uses cookies to collect statistical information on the use of our website with the goal of improving user experience.

Read our cookie policy for more information.
Click here to accept the use of cookies on our website.
Genmab
  • Careers
  • Contact us
  • About Us
    • Company Overview
    • Strategy
    • Our Vision
    • Senior Leadership
    • Board of Directors
    • History
  • Product Pipeline
    • Products in development
      • Daratumumab
      • Ofatumumab
      • Tisotumab vedotin
      • Enapotamab vedotin (HuMax-AXL-ADC)
      • HexaBody-DR5/DR5
      • DuoBody-CD3xCD20
      • Teprotumumab
      • Camidanlumab tesirine
      • HuMax-IL8
      • JNJ-61186372
      • JNJ-63709178
      • JNJ-64007957
      • JNJ-64407564
      • Pre-clinical
    • Clinical Trials
  • Research and Technology
    • Introduction to antibodies
    • Genmab antibody discovery
    • Genmab technology
  • Partnering
    • Our approach
    • Current partnerships
    • Licensing opportunities
      • Technology
  • Investors
    • Genmab News
    • Financial Reports
    • SEC Filings
    • Consolidated Key Figures
    • Stock Information
      • Analyst Coverage
      • Major Shareholders
      • Warrants
      • Restricted Stock Units
    • ADR Program
    • Events & Presentations
    • Financial Calendar
    • Annual General Meeting
    • Investor Portal
    • Corporate Governance
      • Articles of Association
      • Board Committees and Charters
      • Remuneration Principles
      • Code of Business Ethics
    • Corporate Social Responsibility
    • Email Alert Subscription
    • IR Policy
    • FAQ
    • Contact
  • Media
  • Contact Us
    • Office locations
    • Contact form
  • Careers
    • Our culture
    • Meet the team
    • Benefits
    • Current vacancies
  • Privacy
    • Applicants HR Genmab A/S
    • Applicants HR Genmab B.V.
    • Shareholders Genmab A/S
    • IR Subscriptions, Webcasts, Conference Calls
    • Clinical Trials
      • GCT1015-04
      • GCT1021-01
      • GCT1015-05
    • Website Inquiries and Website Use
  • Home >>
  • Investors >>
  • Financial Reports
  • Investors
  • Genmab News
  • Financial Reports
  • SEC Filings
  • Consolidated Key Figures
  • Stock Information
  • ADR Program
  • Events & Presentations
  • Financial Calendar
  • Annual General Meeting
  • InvestorPortal
  • Corporate Governance
  • Corporate Social Responsibility
  • IR Policy
  • FAQ
  • Contact

Shareholder Tools

  • Email Alerts
  • Download Library
  • Snapshot
  • RSS News Feeds

Financial Reports

  • English
  • Danish

Financial Reports

Document Type
Interim Report 3rd Quarter 2000
Interim Report 3rd Quarter 2000

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9

Shareholder Tools

  • Email Alerts
  • Download Library
  • Snapshot
  • RSS News Feeds
  • Accessibility policy
  • Cookie policy
  • Disclaimer
  • Privacy
  • Sitemap
     
   
© 2019 Genmab A/S